MAM
Amagi expands TV ad network to international markets
Indian advertisers can reach more than 200 million viewers worldwide on B4U Network and Zee Bangla across to US, Europe, Asia, GCC, Canada, Africa and Australia.
MUMBAI: Amagi has expanded its India ad network to key international markets like North America, Canada, Africa, Australia and Asia. Amagi will now offer an advertising platform to Indian advertisers with B4U Network and Zee Bangla in these international markets. The company’s move will now enable Indian advertisers to reach more than 200 million viewers on these channels.
The company’s ad network will be extended to Zee Bangla and the entire B4U network including B4U Movies, B4U Music, B4U Plus and B4U Aflam. This opens up doors for several brands within India to expand their advertising footprint across the globe in markets of their choice. While this will instantly help in expanding the consumer base of Indian brands, television networks will also benefit from increased ad revenues.
Amagi co-founder and head of global operations KA Srinivasan said, “Our endeavor is to serve as a global TV ad platform for brands within India, helping them to penetrate and capture international markets essential for business growth; and collaborating with widespread networks like B4U and Zee Bangla, who are our long-standing partners, allows us to do just that. Indian advertisers, who were earlier restricted to Indian audiences alone can now advertise worldwide and reap the benefits of global exposure. Amagi hopes to see more such partnerships with TV channels and continue to bring more Indian brands on board for international advertising.”
Amagi’s global ad network allows advertisers to target audiences across regions, while optimising ad budgets and increasing their return on investments. Advertisers can buy ad spots through Amagi across its international network and target consumers across markets.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
